IP Library › Granted Patent US 12,600,990
Granted Patent B2
US 12,600,990 · App. 18/246,062 · Granted Apr 14, 2026

MRNA induced expression of bone morphogenic protein and receptor and methods related thereto

Inventors: Alexander Day (Cleveland, OH); Bradford Mullin (New Albany, OH)
C12N15/88A61K47/543A61K48/0041C07K14/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,600,990
App. No.
18/246,062
Granted
Apr 14, 2026
Kind
B2
Abstract

Methods and treatments including preparing a synthetic messenger ribonucleic acid (mRNA) encoding at least for a bone morphogenic protein (BMP) and/or a BMP receptor. The synthetic mRNA is lipid-solubilized in a lipid or lipid derivative carrier. Intraoperatively, a bone harvest sample is obtained and incubated with the lipid-solubilized mRNA. The bone harvest sample internalizes at least a portion of the lipid-solubilized mRNA, thereby forming activated BMP and/or BMPR material. The activated BMP and/or BMPR material may be delivered intraoperatively to a bone fusion bed.

Claims (33)

1 . A method comprising:

preparing a synthetic messenger ribonucleic acid (mRNA) encoding at least for a bone morphogenetic protein (BMP);

lipid-solubilizing the synthetic mRNA in a lipid or lipid derivative carrier, thereby forming a lipid-solubilized mRNA;

obtaining a bone harvest sample during a surgical procedure;

incubating the lipid-solubilized mRNA and the bone harvest sample during the surgical procedure, whereby the bone harvest sample internalizes at least a portion of the lipid-solubilized mRNA, thereby forming activated BMP material; and

delivering the activated BMP material to a bone fusion bed during the surgical procedure.

2 . The method of claim 1 , wherein the BMP is selected from the group consisting of BMP2, BMP7, and any combination thereof.

3 . The method of claim 1 , wherein the BMP is BMP2.

4 . The method of claim 1 , wherein the lipid or lipid derivative carrier is selected from the group consisting of tetrakis(8-methylnonyl) 3,3′,3″,3′″-(((methylazanediyl) bis(propane-3,1-diyl)) bis(azanetriyl))tetrapropionate; decyl(2-(dioctylammonio)ethyl)phosphate (9A1P9); ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate (A2-Iso5-2DC18); ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate (A2-Iso5-2DC18); ((4-hydroxybutyl)azanediyl) bis(hexane-6,1-diyl) bis(2-hexyldecanoate) (ALC-0315); 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159); β-sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; bis(2-(dodecyldisulfanyl)ethyl) 3,3′-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazahexacosyl)azanediyl) dipropionate (BAME 016B); 2-(((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide (BHEM-Cholesterol); 1,1′-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl) (2-hydroxydodecyl)amino)ethyl) piperazin-1-yl)ethyl)azanediyl) bis(dodecan-2-ol) (C12-200); 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl) piperazine-2,5-dione (cKK-E12); 3β-[N—(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-Cholesterol); (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate (DLin-MC3-DMA); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); 2,3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA); 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); 1,2-di-O-octadecenyl-3-trimethylammonium-propane (DOTMA); 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); ethylphosphatidylcholine (ePC); hexa (octan-3-yl) 9,9′,9″,9′″,9″″,9′″″-((((benzene-1,3,5-tricarbonyl)yris(azanediyl)) tris (propane-3,1-diyl))tris(azanetriyl))hexanonanoate (FTT5); heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino) octanoate (Lipid H (SM-102)); (((3,6-dioxopiperazine-2,5-iyl)bis(butane-4,1-diyl)) bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9′Z,9″Z,9″Z,12Z,12′Z,12″Z,12″Z)-tetrakis (octadeca-9,12-dienoate) (OF-Deg-Lin); 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG); N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide (TT3); and any combination thereof.

5 . The method of claim 1 , wherein the bone harvest sample is selected from the group consisting of bone dust, bone chips, bone marrow, and any combination thereof.

6 . The method of claim 1 , wherein the bone harvest sample is a combination of bone dust and bone marrow, a combination of bone dust and bone chips, or a combination of bone chips and bone marrow.

7 . The method of claim 1 , wherein the bone harvest sample is a combination of bone dust, bone chips, and bone marrow.

8 . The method of claim 1 , wherein the bone fusion bed is located in long bone, or spinal bone.

9 . The method of claim 1 , wherein the activated BMP material transferred into a scaffold and thereafter performing the delivery.

10 . The method of claim 9 , wherein the scaffold is comprised of a collagen matrix.

11 . The method of claim 1 , wherein the delivery is performed using a subcutaneous port and a catheter, the catheter ending at or near the bone fusion bed.

12 . The method of claim 1 , wherein the synthetic mRNA further encodes for a bone morphogenetic protein receptor.

13 . A method comprising:

preparing a synthetic messenger ribonucleic acid (mRNA) encoding at least for a bone morphogenic protein receptor (BMPR);

lipid-solubilizing the synthetic mRNA in a lipid or lipid derivative carrier, thereby forming a lipid-solubilized mRNA;

obtaining a bone harvest sample;

incubating the lipid-solubilized mRNA and the bone harvest sample, whereby the bone harvest sample internalizes at least a portion of the lipid-solubilized mRNA, thereby forming activated BMPR material; and

delivering the activated BMPR material to a bone fusion bed.

14 . The method of claim 13 , wherein the BMPR is a BMPR type 1.

15 . The method of claim 13 , wherein the bone harvest sample is selected from the group consisting of bone dust, bone chips, bone marrow, and any combination thereof.

16 . The method of claim 13 , wherein the bone harvest sample is a combination of bone dust and bone marrow, a combination of bone dust and bone chips, or a combination of bone chips and bone marrow.

17 . The method of claim 13 , wherein the bone harvest sample is a combination of bone dust, bone chips, and bone marrow.

18 . The method of claim 13 , wherein the bone fusion bed is located in long bone, or spinal bone.

19 . The method of claim 13 , wherein the activated BMP material transferred into a scaffold and thereafter performing the delivery.

20 . A method comprising:

obtaining a bone harvest sample during a surgical procedure;

incubating the bone harvest sample and a lipid-solubilized synthetic messenger ribonucleic acid (mRNA) encoding at least for a bone morphogenetic protein (BMP) during the surgical procedure, whereby the bone harvest sample internalizes at least a portion of the lipid-solubilized mRNA, thereby forming activated BMP material; and

delivering the activated BMP material to a bone fusion bed during the surgical procedure.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2025
From: MULLIN, BRADFORD
To: MULLIN PATENTS, LLC
Reel/Frame 071250/0526 →
Continuity (2)
Provisional Application 63252373 · Oct 5, 2021
Related Publication 20240200101A1 · Jun 20, 2024
References Cited (41)
US 20100119492A1 · Hans · 2010 [cited by examiner]
US 20180214572A1 · Balmayor · 2018 [cited by examiner]
KR 20110132579A · 2011 [cited by applicant]
WO 2016118697A1 · 2016 [cited by applicant]
WO 2021003300A1 · 2021 [cited by applicant]
R. Gao, et al. “Human Spinal Bone Dust as a Potential Local Autograft,” Spine 43 (4), 2018, E193-199. (Year: 2018). [cited by examiner]
S. Du Pen. “Implantable Spinal Catheter and Drug Delivery Systems: Complications,” Techniques in Regional Anesthesia and Pain Management 2.3 (1998): 152-160. (Year: 1998). [cited by examiner]
A. McArdle et al. “Positive selection for bone morphogenetic protein receptor type-IB promotes differentiation and specification of human adipose-derived stromal cells toward an osteogenic lineage,” Tissue Engineering: … [cited by examiner]
International Search Report and Written Opinion issued Jan. 30, 2023 for PCT/US2022/077467, 8 pages. [cited by applicant]
Mcardle et al., “Positive selection for bone morphogenetic protein receptor type-IB promotes differentiation and specification of human adipose-derived stromal cells toward an osteogenic lineage,” Tissue Engineering: Pa… [cited by applicant]
Carragee et al., “A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned,” The Spine Journall: Official Journal of the North American S… [cited by applicant]
Geng et al., “BMP-2 and VEGF-A modRNAs in collagen scaffold synergistically drive bone repair through osteogenic and angiogenic pathways,” Communications Biology, 4(1), 2021, https://doi.org/10.1038/S42003-020-01606-9. [cited by applicant]
Katagiri et al., “Bone Morphogenetic Proteins,” Cold Spring Harbor Perspectives in Biology, 8(6), 2016, https://doi.org/10.1101/CSHPERSPECT.A021899. [cited by applicant]
Tannoury et al., “Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery,” The Spine Journal, 14(3), 552-559, 2014, https://doi.org/10.1016/J.SPINEE.2013.08.060. [cited by applicant]
Anttila et al., “Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial,” Molecular Therapy—Methods & Clinical Development, 18, 464-472, 2020, https://… [cited by applicant]
Balmayor et al., “Chemically modified RNA induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats,” Biomaterials, 87, 131-146, 2016, https://doi.org/10.1016/J.BIOMATERIAL… [cited by applicant]
Bragdon et al., “Bone morphogenetic proteins: a critical review,” Cellular Signalling, 23(4), 609-620, 2011, https://doi.org/10.1016/J.CELLSIG.2010.10.003. [cited by applicant]
Collen et al., “VEGFA mRNA for regenerative treatment of heart failure,” Nature Reviews Drug Discovery, 2021 21:1, 21(1), 79-80. https://doi.org/10.1038/s41573-021-00355-6. [cited by applicant]
Elkhalifa et al., “Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases,” Biomedicine & Pharmacotherapy, 145, 112385, 2022, https://doi.org/10.1016/J… [cited by applicant]
Epstein, “Pros, cons, and costs of INFUSE in spinal surgery,” Surgical Neurology International, 2(1), 2011, https://doi.org/10.4103/2152-7806.76147. [cited by applicant]
Epstein, “Complications due to the use of BMP/INFUSE in spine surgery: The evidence continues to mount,” Surgical Neurology International, 4(Suppl 5), S343, 2013, https://doi.org/10.4103/2152-7806.114813. [cited by applicant]
Faundez et al., “Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review,” International Orthopaedics, 40(6), 1309-1319, 2016, https://doi.org/10.1007/S00264-016-3149-8. [cited by applicant]
Gao et al., “Human Spinal Bone Dust as a Potential Local Autograft In Vitro Potent Anabolic Effect on Human Osteoblasts,” 2018, https://doi.org/10.1097/BRS.0000000000002331. [cited by applicant]
Hou et al., “Lipid nanoparticles for mRNA delivery,” Nature Reviews Materials 2021, 1-17. https://doi.org/10.1038/s41578-021-00358-0. [cited by applicant]
Ichiyanagi et al., “Isolation of mesenchymal stem cells from bone marrow wastes of spinal fusion procedure (TLIF) for low back pain patients and preparation of bone dusts for transplantable autologous bone graft with a … [cited by applicant]
Kariko et al., “Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability,” Molecular Therapy, 16(11), 1833-1840,2008, https://doi.org/… [cited by applicant]
Khorsand et al., “A Comparative Study of the Bone Regenerative Effect of Chemically Modified RNA Encoding BMP-2 or BMP-9,” AAPS Journal, 19(2), 2017, 438-446. [cited by applicant]
Kormann et al., “Expression of therapeutic proteins after delivery of chemically modified mRNA in mice,” Nature Biotechnology 2011 29:2, 29(2), 154-157. https://doi.org/10.1038/nbt.1733. [cited by applicant]
Mannion et al., “Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2—but what is the cost?” The Spine Journall: Official Journal of the North American Spine Soc… [cited by applicant]
Nohe et al., “Signal transduction of bone morphogenetic protein receptors,” Cellular Signalling, 16(3), 291-299, 2004, https://doi.org/10.1016/j.cellsig.2003.08.011. [cited by applicant]
Sahin et al., “mRNA-based therapeutics—developing a new class of drugs,” Nature Reviews Drug Discovery 2014 13:10, 13(10), 759-780. https://doi.org/10.1038/nrd4278. [cited by applicant]
Sanchez-Duffhues et al., “Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors,” Bone, 138, 115472, 2020, https://doi.org/10.1016/J.BONE.2020.115472. [cited by applicant]
Boden et al., “Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies,” Spine,… [cited by applicant]
Boden et al., “The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report,” Spine, 25(3), 376-381, 2000, https://doi.org/10.1097/00007632-200002010-00020. [cited by applicant]
Behzadi et al., “Cellular uptake of nanoparticles: journey inside the cell,” Chemical Society Reviews, 46(14), 4218-4244, 2017, https://doi.org/10.1039/C6CS00636A. [cited by applicant]
David et al., “Lumbar spinal fusion using recombinant human bone morphogenetic protein in the canine. A comparison of three dosages and two carriers,” Spine, 24(19), 1973-1979, 1999, https://doi.org/10.1097/00007632-199… [cited by applicant]
James et al., “A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2,” Tissue Eng Part B Rev., Aug. 22, 2016(4):284-97. doi: 10.1089/ten.TEB.2015.0357. [cited by applicant]
Wang et al., “Bone Morphogenetic Protein (BMP) signaling in development and human diseases,” Genes & Diseases, 1(1), 87-105, 2014, https://doi.org/10.1016/J.GENDIS.2014.07.005. [cited by applicant]
Yu et al., “Cell-mediated delivery of VEGF modified mRNA enhances blood vessel regeneration and ameliorates murine critical limb ischemia,” Journal of Controlled Release, 310, 103-114, 2019, https://doi.org/10.1016/J.JC… [cited by applicant]
Zhang et al., “Demineralized Bone Matrix Carriers and their Clinical Applications: An Overview,” Orthopaedic Surgery, 11(5), 725, 2019, https://doi.org/10.1111/OS.12509. [cited by applicant]
Schimandle et al., “Experimental spinal fusion with recombinant human bone morphogenetic protein-2,” Spine, 20(12), 1326-1337, 1995, https://europepmc.org/article/med/7676329. [cited by applicant]